Science

Apr 25, 2025, 13:27

Myeloma Paper of the Day, April 25th, suggested by Robert Orlowski

Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: For patients receiving quad induction, MRD<10-5 was 29% (<10-6 15%) and 59% post-ASCT (<10-6 45%); ASCT lowered MRD >1 log in 69%; quad (vs. triplet) did not reduce effect of ASCT; reduction in most pronounced in high-risk patients.”

“Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy”

Authors: Susan Bal, Tylan Magnusson, Gayathri Ravi, Smith Giri, Kelly Godby, Binod Dhakal, Natalie Callander, Rebecca Silbermann, Bhagirathbhai Dholaria, Vishnu Reddy, Luciano Costa.

More posts featuring Robert Orlowski.

Bhagirathbhai Dholaria Binod Dhakal cancer Gayathri Ravi Kelly Godby Luciano Costa multiple myeloma Myeloma Paper of the Day Natalie Callander OncoDaily Oncology Rebecca Silbermann Robert Orlowski Smith Giri Susan Bal T-cell therapy Tylan Magnusson Vishnu Reddy

Senate President Passes Away After Brave Battle with Cancer: Dominick J. Ruggerio

Where to Study to Become ASCO President: 2025 Institutional Rankings

Yelak Biru: UK grants first approval for Blenrep in multiple myeloma

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

Dr. Don Dizon and Dr. Nathan Pennell Reflect on the Evolution of the ASCO Educational Book